Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification

• Published in: Seminars in nephrology Vol. 31; no. 4; p. 341
• Main Authors: Sethi, Sanjeev, Fervenza, Fernando C
• Format: Journal Article
• Language: English
• Published: United States 01.07.2011
• Subjects: Complement C3 - metabolism; Complement Pathway, Alternative; Glomerulonephritis, Membranoproliferative - classification; Glomerulonephritis, Membranoproliferative - etiology; Glomerulonephritis, Membranoproliferative - immunology; Glomerulonephritis, Membranoproliferative - pathology; Humans
• ISSN: 1558-4488
• DOI: 10.1016/j.semnephrol.2011.06.005

Membranoproliferative glomerulonephritis (MPGN) is a pattern of injury that results from subendothelial and mesangial deposition of Igs caused by persistent antigenemia and/or circulating immune complexes. The common causes of Ig-mediated MPGN include chronic infections, autoimmune diseases, and monoclonal gammopathy/dysproteinemias. On the other hand, MPGN also can result from subendothelial and mesangial deposition of complement owing to dysregulation of the alternative pathway (AP) of complement. Complement-mediated MPGN includes dense deposit disease and proliferative glomerulonephritis with C3 deposits. Dysregulation of the AP of complement can result from genetic mutations or development of autoantibodies to complement regulating proteins with ensuing dense deposit disease or glomerulonephritis with C3 deposits. We propose a new histologic classification of MPGN and classify MPGN into 2 major groups: Ig-mediated and complement-mediated. MPGN that is Ig-mediated should lead to work-up for infections, autoimmune diseases, and monoclonal gammopathy. On the other hand, complement-mediated MPGN should lead to work-up of the AP of complement. Initial AP screening tests should include serum membrane attack complex levels, an AP functional assay, and a hemolytic assay, followed by tests for mutations and autoantibodies to complement-regulating proteins.